StockNews.com upgraded shares of Pulse Biosciences (NASDAQ:PLSE – Free Report) to a sell rating in a report published on Thursday morning.
Pulse Biosciences Price Performance
NASDAQ PLSE opened at $17.14 on Thursday. The stock’s fifty day moving average is $17.65 and its two-hundred day moving average is $16.36. Pulse Biosciences has a fifty-two week low of $6.59 and a fifty-two week high of $22.69.
Pulse Biosciences (NASDAQ:PLSE – Get Free Report) last announced its quarterly earnings results on Wednesday, October 30th. The company reported ($0.21) earnings per share for the quarter. During the same quarter in the previous year, the business earned ($0.19) EPS.
Institutional Trading of Pulse Biosciences
About Pulse Biosciences
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
Featured Stories
- Five stocks we like better than Pulse Biosciences
- Expert Stock Trading Psychology Tips
- 3 Small-Cap Stocks With Big Growth Potential
- The How and Why of Investing in Gold Stocks
- WallStreetBets: How a Reddit Forum Shook Up Stock Market Dynamics
- How to Calculate Stock Profit
- Are 2024’s Top Insider Buys a Good Bet for 2025?
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.